Umdlavuza webele nowamaqanda
Uma uyisiguli somdlavuza webele kanye nesibeletho, uthola ukuthi ungumdlavuza wenguquko ye-BRCA1/2 ngemva kokudlula ukuhlolwa kofuzo, futhi impilo yakho iyasindiswa. Ngokusho kwe-Global Oncologist Network, i-Niraparib, isidakamizwa esihlosiwe esiqondiswe kufuzo lwe-PARP, sizothunyelwa ukuze simakethwe ngekota yesine yalo nyaka ngenxa yemiphumela yokuhlolwa komtholampilo yesigaba sesi-III esimangalisayo. Ngenxa yedatha yokuhlolwa komtholampilo emangalisayo yalo muthi, kungaqiniseka Kuqinisekile ukuthi umuthi uzogunyazwa yi-FDA. Intengo yesitoko yenkampani ehlosiwe yokuthuthukisa izidakamizwa iTesaro inyuke isuka ku-$37 yaya ku-$77 ngaso leso sikhathi ngenxa yalokhu kuphumelela.
Hlobo luni lomuthi iNiraparib?
It is an oral targeted drug that targets the PARP gene and is not effective for any cancer. It mainly targets cancers with mutations in the BRCA1 / 2 gene, such as umdlavuza wesibeletho and breast cancer. It reflects the “precision treatment” concept of modern medicine. Patients with ovarian and umdlavuza webele need genetic testing to find out if they have a BRCA1 / 2 mutation.
Kumangalisa kangakanani ukwelashwa kwe-Niraparib?
U-Tesaro ukhiphe idatha yomtholampilo yeSigaba III se-Niraparib yeziguli ezinomdlavuza wesibeletho eziphinde zabuyela emuva ngemuva kwe-chemotherapy ethuthukisiwe. Imiphumela yabonisa ukuthi kumdlavuza we-ovarian nge-BRCA gene mutation, i-Niraparib yayithathwa ngomlomo kanye ngosuku, futhi ukusinda okungenasifo okuvamile kwakuyizinyanga ezingu-21, kuyilapho iqembu elilawulayo (Iziguli ezathola i-chemotherapy kuphela) lalinokusinda-mahhala kwezinyanga ezingu-5.5. . Izinyanga ezingama-21 vs 5.5 izinyanga, isikhathi sokusinda cishe siphindwe izikhathi ezi-4! Lesi sibalo siyethusa kakhulu, ngoba ukuphila isikhathi eside kwemithi emisha eminingi kuyizinyanga ezimbalwa kuphela. Ngamanye amazwi, iziguli ezinezinguquko ze-BRCA ezisebenzisa i-Niraparib zingaphila ngokwesilinganiso ngaphezu kwezinyanga ezingama-21. Lokhu kuyamangalisa kakhulu ezigulini ezinomdlavuza we-ovarian oqhubekayo oqhubekayo.
Hlobo luni lomdlavuza iNiraparib engelapheka?
I-PARP kanye ne-BRCA yizakhi zofuzo ezimbili eziyinhloko ezinesibopho sokulungisa ukuguqulwa kwe-DNA kumaseli, futhi "ziyindlela yokuvikela kwesokudla nesobunxele" ukuvikela impilo yamaseli ethu. Ngenxa yethonya lemvelo, ukuguqulwa kwe-DNA kwenzeka emzimbeni wethu nganoma isiphi isikhathi, noma kuphi, kodwa ngenxa yokuba khona kwalezi zindlela ezimbili zokuvikela, ngemva kokuqinisekiswa kokuguqulwa kwe-DNA, ngaphezu kwe-99.9999% ingalungiswa ngempumelelo, ngaphandle kwalokho isigameko somdlavuza. izoba phezulu kakhulu kunamanje .
Kodwa kwabanye abantu, ngenxa yezizathu zokuzalwa noma ezitholiwe, isakhi sofuzo seseli ye-BRCA ngokwaso siyaguqulwa futhi silahlekelwe umsebenzi walo, ngakho-ke amathuba okulungisa ngemva kokuguqulwa kwe-DNA kuncipha kakhulu, futhi ukuguqulwa kofuzo okuningi kuzoqoqwa ngokushesha. Amathuba okuba nomdlavuza kuleli qembu anda kakhulu.
Although PARP inhibitors are mainly targeted at breast and ovarian cancer, some patients with other cancers also carry BRCA mutations or other DNA repair defects. They theoretically use PARP-targeted drugs to work well, including some umdlavuza wendlala yesinye. , Fallopian tube cancer, pancreatic cancer, childhood i-acute myeloid leukemia, etc. Clinical trials for these cancers are ongoing, and the world is waiting to see the results.
